2026-03-11

Media Spotlight: Cangzhou Radio and Television Station | A New Chapter in Collaborative Development: Moving Forward with Innovation—Cangzhou Strives to Build a Premier Hub for the Pharmaceutical Industry

Media Spotlight: Cangzhou Radio and Television Station | A New Chapter in Collaborative Development: Moving Forward with Innovation—Cangzhou Strives to Build a Premier Hub for the Pharmaceutical Industry

Learn more

2026-02-19

China Pharmaceutical News 2026 Spring Festival Grassroots Visit | Greening the API Production Line

China Pharmaceutical News 2026 Spring Festival Grassroots Visit | Greening the API Production Line

Learn more

2026-01-28

Media Spotlight: Cangzhou Daily | Carbon Footprint Certification Opens the “Green Passport” to International Markets

Media Spotlight: Cangzhou Daily | Carbon Footprint Certification Opens the “Green Passport” to International Markets

Learn more

Media Spotlight · Cangzhou Daily | Hebei Guangxiang Pharmaceutical: Secures the “Green Pass” for International Trade

Recently, Shijiazhuang Customs awarded Hebei Guangxiang Pharmaceutical Co., Ltd. the Certificate of Authorized Economic Operator (AEO) for Advanced Certification, making it the only pharmaceutical company in the province to obtain AEO status this year. This milestone signifies that the company has officially been recognized as an enterprise with the highest credit rating under customs supervision.

20

2025/12

Media Spotlight – Hebei Daily | Optimizing Service Measures to Build a Robust Ecosystem for Project Development

During the 14th Five-Year Plan period, Cangzhou City has steadfastly regarded the construction of key projects as the cornerstone and powerful engine for high-quality development, making all-out efforts to ensure their successful implementation. This year, the city is undertaking 797 key construction projects with a total investment of RMB 477.12 billion, including 418 provincial- and municipal-level key projects. Recently, reporters visited several key project sites to gain firsthand insight into the city’s dynamic efforts to accelerate its transformation into a modern, coastal economic powerhouse by leveraging project development as a strategic driver.

17

2025/12

Media Spotlight – Hebei Economic Daily | Pressing the “Fast-Forward” Button on Internationalization: Guangxiang Pharmaceutical Obtains Customs AEO Advanced Certification

On December 10, Shijiazhuang Customs awarded the Advanced Authorized Economic Operator (AEO) Certificate to Hebei Guangxiang Pharmaceutical Co., Ltd. of Shijiazhuang Sihua Pharmaceutical Group (hereinafter referred to as “Guangxiang Pharmaceutical”), making it the only pharmaceutical company in the province to date this year to obtain AEO certification from Customs.

16

2025/12

Kudos! Lü Xiaolong, a post-2000s employee of Guangxiang Pharmaceutical under Shijiazhuang Sihua Pharmaceutical Group, has successfully donated hematopoietic stem cells.

On the morning of February 27, in the hematopoietic stem cell collection room of the Third Hospital of Hebei Medical University, a post-2000s young man successfully donated 395 milliliters of hematopoietic stem cell suspension after more than five hours of collection. These “seeds of life,” destined for recipients far away, carry with them profound love and the hope of renewed vitality. The young man is Lü Xiaolong, who works in the Warehousing Services Department of Hebei Guangxiang Pharmaceutical Co., Ltd., part of Shijiazhuang Sihua Pharmaceutical Group. He is also the second employee from the group to successfully donate hematopoietic stem cells.

13

2023/03

Portrait of “Little Giant” Cities — Cangzhou, Hebei: Anchoring on Specialization, Precision, Distinctiveness, and Innovation to Unleash the Momentum of “Little Giants”

At present, Hebei Guangxiang Pharmaceutical Co., Ltd. has embarked on a journey to strive for the national-level “Little Giant” designation for specialized, refined, distinctive, and innovative enterprises. The company has identified untapped market opportunities and is poised to deepen its expertise in the niche area of specialty active pharmaceutical ingredients. Leveraging a suite of national, provincial, and municipal policies and initiatives supporting the development of the biopharmaceutical industry, the company is steadily increasing its R&D investment, continuously elevating its corporate performance, and achieving new leaps forward.

13

2022/11

Shisi Pharmaceutical Accelerates High-Quality Development of Active Pharmaceutical Ingredients and Moves Toward Becoming a Leading API Manufacturer

Against the backdrop of implementing the nation’s new development philosophy and transitioning China from a major pharmaceutical producer to a leading pharmaceutical powerhouse, Shijiazhuang No.4 Pharmaceutical Group—one of China’s top 100 pharmaceutical companies (hereinafter referred to as “Shijiazhuang No.4”)—is vigorously pursuing a “API-plus-formulation” development strategy. Through strategic capital partnerships, acquisitions, and corporate restructuring, the company is actively expanding its upstream and downstream value chain, strengthening its competitiveness in both domestic and international markets, and injecting fresh momentum into the accelerated deployment and growth of its API business segment. A series of major initiatives are propelling Shijiazhuang No.4 Pharmaceutical Group toward its goal of becoming a leading API manufacturer.

23

2022/05

Guangxiang Pharmaceutical of Shijiazhuang Sihua Pharmaceutical Group: Delivering a “Combination Punch” of Innovation to Seize the Initiative in Development

Its flagship product, caffeine, has seen robust growth across both production and sales; seven new specialty API products, including pentoxifylline and ornidazole, are poised for approval and market launch; and in the first quarter, its core business revenue posted triple-digit growth. Since the beginning of this year, Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, has delivered a powerful “combination punch,” securing a strong start to its innovative development.

20

2022/04

Special Report: The Spirit of the Sixth Plenary Session Takes Root at Shisiyao Group’s Guangxiang Pharmaceutical | Innovation and Bold Progress Drive Products to Global Markets

Sharing feelings, recounting insights, and discussing the future... On November 23, in the Party and Mass Activities Room of Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, 20 Party members sat together, each taking turns to express their thoughts and experiences in studying the spirit of the Sixth Plenary Session of the 19th CPC Central Committee. The atmosphere was vibrant and enthusiastic, with everyone brimming with confidence about the future.

20

2022/01